<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Stock Blog Hub &#187; Micrus Endovascular</title>
	<atom:link href="http://www.stockbloghub.com/tag/micrus-endovascular/feed" rel="self" type="application/rss+xml" />
	<link>http://www.stockbloghub.com</link>
	<description>Start Your Investing Research Here!</description>
	<lastBuildDate>Wed, 23 May 2012 20:22:08 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.3.2</generator>
		<item>
		<title>(MEND) Mircrus Endovascular Corporation Estimates Swing to Profit</title>
		<link>http://www.stockbloghub.com/2009/09/10/mend-mircrus-endovascular-corporation-estimates-swing-to-profit/14819</link>
		<comments>http://www.stockbloghub.com/2009/09/10/mend-mircrus-endovascular-corporation-estimates-swing-to-profit/14819#comments</comments>
		<pubDate>Thu, 10 Sep 2009 21:39:06 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Appliances & Equipment]]></category>
		<category><![CDATA[MEND]]></category>
		<category><![CDATA[Micrus Endovascular]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=14819</guid>
		<description><![CDATA[Micrus Endovascular Corp (MEND) posted an unexpected profit last quarter and estimates have spiked. Company Description Micrus develops, manufactures, and markets implantable and disposable devices for that treat cerebral vascular diseases. The company&#8217;s footprint extends across the Americas, Europe, and Asia. Healthy Profits Most analysts were expecting Micrus to report a loss on Aug 6, when the company shocked the Street with a 14 cent per share profit. The Zacks consensus estimate was a 2 cent loss at the time of the announcement. Net income for the first quarter of fiscal 2010 was $2.3 million, up from a loss of $6.6 million in the same quarter last year. Revenue rose 16% to just over $21 million, with about half coming from the U.S. Micrus finished the quarter with almost $20 ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/09/10/mend-mircrus-endovascular-corporation-estimates-swing-to-profit/14819/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MEND) Micrus Finds Neurovascular Partner</title>
		<link>http://www.stockbloghub.com/2009/08/26/mend-micrus-finds-neurovascular-partner/13506</link>
		<comments>http://www.stockbloghub.com/2009/08/26/mend-micrus-finds-neurovascular-partner/13506#comments</comments>
		<pubDate>Wed, 26 Aug 2009 20:50:18 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Appliances & Equipment]]></category>
		<category><![CDATA[MEND]]></category>
		<category><![CDATA[Micrus Endovascular]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=13506</guid>
		<description><![CDATA[Micrus Endovascular (MEND) recently inked a partnership deal with New Jersey-based Flexible Stenting Solutions for developing a new technology to treat some neurovascular indications. Flow diversion targets large and giant aneurysms, which represent nearly 20%-25% of treated intracranial aneurysms. The stent-like devices, when placed in the parent vessel, divert blood flow away from the aneurysm to facilitate healing. Micrus will manage the regulatory and clinical process and also manufacture flow diverters based on Flexible Stenting&#8217;s proprietary third-generation self-expanding stent design platform. This advanced platform provides porosity and flow-diversion control based on a unique design pattern and raises flexibility during delivery and post-placement vessel conformability. It also allows post-placement coiling, if required, and its proprietary coating lowers the possibility of thrombogenicity and stenosis. Micrus has already made an upfront payment following ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/08/26/mend-micrus-finds-neurovascular-partner/13506/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MEND) Micrus Endovascular &#8211; Forecasts are averaging 27 cents, a 421% year-over-year earnings increase</title>
		<link>http://www.stockbloghub.com/2009/08/11/micrus-endovascular-forecasts-are-averaging-27-cents-a-421-year-over-year-earnings-increase/12295</link>
		<comments>http://www.stockbloghub.com/2009/08/11/micrus-endovascular-forecasts-are-averaging-27-cents-a-421-year-over-year-earnings-increase/12295#comments</comments>
		<pubDate>Tue, 11 Aug 2009 20:45:51 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Appliances & Equipment]]></category>
		<category><![CDATA[MEND]]></category>
		<category><![CDATA[Micrus Endovascular]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=12295</guid>
		<description><![CDATA[Micrus Endovascular Corp (MEND) posted an unexpected profit last week on increased revenue. Company Description Micrus develops, manufactures, and markets implantable and disposable devices for that treat cerebral vascular diseases. The company&#8217;s footprint extends across the Americas, Europe, and Asia. Healthy Profits Most analysts were expecting Micrus to report a loss on Aug 6, when the company shocked the Street with a 14 cent per share profit. The Zacks consensus estimate was a 2 cent loss at the time of the announcement. Net income for the first quarter of fiscal 2010 was $2.3 million, up from a loss of $6.6 million in the same quarter last year. Revenue rose 16% to just over $21 million, with about half coming from the U.S. Micrus finished the quarter with almost $20 million ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/08/11/micrus-endovascular-forecasts-are-averaging-27-cents-a-421-year-over-year-earnings-increase/12295/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

